Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | January 05, 2023 | January 09, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Skye Bioscience, Inc.
Report date January 05, 2023 · Filed January 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.02 · Expires 2033-01-05 | Direct | 250,000 |
Reported balance
After 2023-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-05 · Grant · Acquired 250,000 · Balance 250,000 F1: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning November 10, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning November 10, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2023 Filed Jan 9, 2023 15:30 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.02 Strike: $0.02 | $4,250.00 |
DisclosureSEC source: 0001516551-23-000008 · wf-form4_167327820816124.xml · derivative · entry 1 Rai Sukhwinder Singh · CIK 0001947352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-05 F1 · derivative.exercise_date: The option grant shall be exercisable for a price of $0.017 per option share for ten years from January 5, 2023 and the options will vest in equal monthly installments over the one year period beginning November 10, 2022. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 17:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 195,000 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 6 Rai Sukhwinder Singh · CIK 0001947352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2025-08-03 F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F7 · derivative.exercise_date: 8.33% of the options vested on the grant date of August 3, 2020. 8.33% of the options vest, or have vested, on each monthly anniversary of the grant date. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 17:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 146,250 | Not disclosed Strike: $0.11 | Not disclosed |
DisclosureSEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 5 Rai Sukhwinder Singh · CIK 0001947352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 146,250 shares Expires 2025-02-06 F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F6 · derivative.exercise_date: The options vest, or have vested, in equal installments on each of February 6, 2020, February 6, 2021, February 6, 2022, February 6, 2023. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 17:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 146,250 | Not disclosed Strike: $1.71 | Not disclosed |
DisclosureSEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 4 Rai Sukhwinder Singh · CIK 0001947352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,250 Underlying: Common Stock · 146,250 shares Expires 2022-12-22 F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F5 · derivative.exercise_date: The options underlying this award are fully vested. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 17:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantStock Option (Right to Buy) · Derivative | 390,000 | Not disclosed Strike: $1.60 | Not disclosed |
DisclosureSEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · derivative · entry 3 Rai Sukhwinder Singh · CIK 0001947352 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,000 Underlying: Common Stock · 390,000 shares Expires 2024-04-02 F4 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F4 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. F5 · derivative.exercise_date: The options underlying this award are fully vested. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 17:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 73,561 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · nonDerivative · entry 2 Rai Sukhwinder Singh · CIK 0001947352 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by wife of Reporting Person Disclosed balance after: 73,561 F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). F3 · balance_after: For each indirect account, Mr. Rai disclaims beneficial ownership except to the extent of his pecuniary interest, if any. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 17:24 UTC | Skye Bioscience, Inc. SKYE · Entity 8098 | GrantCommon Stock | 22,157 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001516551-22-000045 · wf-form4_166853302798842.xml · nonDerivative · entry 1 Rai Sukhwinder Singh · CIK 0001947352 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 22,157 F1 · kind: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). F1 · price: The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). F2 · ownership.nature: The shares are held through the Canaccord Genuity Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.